Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension

Post-Marketing Surveillance Study Micardis® Plus

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02238275

Enrollment

8135

Registered

2014-09-12

Start date

2002-06-30

Completion date

Unknown

Last updated

2014-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Study to evaluate efficacy and tolerability of Micardis® plus under usual daily-practice prescribing-conditions

Interventions

DRUGMicardis® plus

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult (Age \>= 18 years) males and females for whom a medical antihypertensive therapy is indicated

Exclusion criteria

* Age \< 18 years

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline in morning blood pressure	Baseline, after 6 weeks	—
Change from baseline in classification of blood pressure	Baseline, after 6 weeks	according to Word Health Organisation - Isolated systolic hypertension (WHO-ISH) - definition of 'Deutsche Hochdruckliga'

Secondary

Measure	Time frame
Change from baseline in heart rate	Baseline, after 6 weeks
Number of patients with adverse drug reactions	up to 6 weeks
Assessment of efficacy by investigator on 5-point scale	after 6 weeks
Assessment of tolerability by investigator on a 5-point scale	after 6 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026